CompletedInterventionalPhase 1Last updated Nov 2, 2016

A Study of RO5285119 in Healthy Volunteers

A Single- and Multiple Ascending-Dose, Randomized, Double-Blind, Placebo-Controlled Study in Two Single-Center Study Parts to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5285119 Following Oral Administration in Healthy Subjects

Overview

ClinicalTrials.gov ID: NCT01418963
Lead Sponsor: Hoffmann-La RocheINDUSTRY
Brief Summary: This two-part, randomized, double-blind, placebo-controlled study will assess the safety, pharmacokinetics and pharmacodynamics of single and multiple ascending oral doses of RO5285119 in healthy volunteers. Anticipated time on study will be up to 9 weeks for each subject.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Jul 2011
Primary Completion Date: Jul 2012Actual
Completion Date: Jul 2012Actual

Study Record Dates

First Submitted: Aug 15, 2011
First Submitted that Met QC Criteria: Aug 16, 2011
First Posted: Aug 17, 2011Estimated
Last Update Submitted that Met QC Criteria: Nov 1, 2016
Last Update Posted: Nov 2, 2016Estimated
Last Verified: Nov 2016

NCT01398241Completed

A Study of RO5267683 in Healthy Subjects

NCT01664143Completed

A Single-Center Study of RO5508887 in Healthy Volunteers

NCT01864226Completed

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 in Healthy Volunteers

NCT01461967Completed

A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers

NCT01893437Completed

A Study of RO6799477 in Healthy Volunteers

NCT01209221Completed

A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers